A forum for researchers, clinicians, and patients to discuss Janus kinase biology, JAK inhibitor therapies, and the latest developments in JAK-STAT signaling.
Posted by biochemist_dr_lee · 48 replies
Janus kinases are a family of four non-receptor tyrosine kinases: JAK1, JAK2, JAK3, and TYK2. JAK1 and JAK2 are ubiquitously expressed, while JAK3 expression is largely restricted to hematopoietic cells, and TYK2 is found in most tissues. They differ primarily in their cytokine receptor associations: JAK2 is essential for signaling through receptors for erythropoietin and growth hormone, while JAK3 pairs exclusively with the common gamma chain (γc) of cytokine receptors. Selective inhibition of each isoform produces distinct therapeutic and safety profiles.
Posted by cellbiologystudent · 52 replies
When a cytokine binds to its receptor, the associated JAK kinases transphosphorylate each other, becoming activated. Activated JAKs then phosphorylate specific tyrosine residues on the receptor, creating docking sites for STAT (Signal Transducer and Activator of Transcription) proteins. STATs bind to these phosphorylated receptor sites through their SH2 domains, become phosphorylated by JAKs themselves, then dimerize and translocate to the nucleus where they act as transcription factors. The entire cascade from cytokine binding to gene expression changes can occur within minutes.
Posted by rheumatology_nurse · 61 replies
Tofacitinib (Xeljanz) was the first JAK inhibitor approved by the FDA for rheumatoid arthritis, receiving approval in 2012, while baricitinib (Olumiant) was approved in 2018. Tofacitinib primarily inhibits JAK1 and JAK3, whereas baricitinib inhibits JAK1 and JAK2. Clinical trials suggest comparable efficacy for both agents in reducing RA disease activity as measured by the ACR20/50/70 response criteria. The two drugs differ somewhat in dosing, half-life, and renal excretion profiles, which can influence prescribing decisions in patients with comorbidities.
Posted by clinical_pharmacist_v · 57 replies
In 2021 and 2022, the FDA updated the black box warnings for all JAK inhibitors based on safety data from the ORAL Surveillance trial with tofacitinib, which showed increased risks of serious adverse events including major adverse cardiovascular events (MACE), malignancy, thrombosis, and mortality compared to TNF inhibitors in patients with RA who were 50 years or older with cardiovascular risk factors. These warnings now apply class-wide to all approved JAK inhibitors. The FDA also restricted the use of these drugs to patients who have had an inadequate response to TNF blockers. Ongoing monitoring and risk-benefit discussions are essential when prescribing these agents.
Posted by hematology_fellow · 43 replies
Ruxolitinib (Jakafi) is a JAK1/JAK2 inhibitor that was the first JAK inhibitor approved by the FDA, receiving approval in 2011 for myelofibrosis, a rare bone marrow cancer. It was subsequently approved for polycythemia vera in 2014 and acute and chronic graft-versus-host disease (GVHD) in 2019 and 2021 respectively. Ruxolitinib works by reducing the constitutive JAK-STAT signaling driven by the JAK2 V617F mutation present in the majority of myelofibrosis and polycythemia vera patients. It significantly reduces spleen volume and improves disease-related symptoms in myelofibrosis.
Posted by patient_advocate_ra · 66 replies
TNF inhibitors such as adalimumab and etanercept are injectable biologic agents that block the pro-inflammatory cytokine tumor necrosis factor-alpha, while JAK inhibitors are small molecule oral drugs that block intracellular signaling downstream of multiple cytokine receptors. JAK inhibitors offer the convenience of oral administration compared to injection or infusion for biologics. Efficacy for both classes is generally comparable in patients who have failed methotrexate, though head-to-head data is limited. The safety profiles differ: biologics carry higher infection risk from specific pathogens like tuberculosis, while JAK inhibitors have the class-wide cardiovascular and malignancy warnings.
Posted by immunogenetics_prof · 39 replies
The STAT family consists of seven members: STAT1, STAT2, STAT3, STAT4, STAT5A, STAT5B, and STAT6. STAT1 is critical for interferon signaling and anti-viral defense; gain-of-function STAT1 mutations cause chronic mucocutaneous candidiasis. STAT3 gain-of-function mutations cause an immune dysregulation syndrome with autoimmunity and lymphoproliferation. STAT5B mutations cause growth hormone insensitivity and immune deficiency. STAT6 gain-of-function mutations have been identified in patients with severe atopic dermatitis. Understanding these pathways guides targeted therapy selection in both autoimmune and neoplastic disease.
Posted by dermatology_resident · 54 replies
Yes, JAK inhibitors have received FDA approvals across multiple conditions. Upadacitinib (Rinvoq) and abrocitinib (Cibinqo) are approved for moderate-to-severe atopic dermatitis. Upadacitinib is also approved for psoriatic arthritis, ankylosing spondylitis, Crohn's disease, and ulcerative colitis. Baricitinib received emergency use authorization for hospitalized COVID-19 patients requiring oxygen supplementation. Ruxolitinib cream (Opzelura) is approved for atopic dermatitis and non-segmental vitiligo. The expanding approvals reflect the central role of JAK-STAT signaling across multiple inflammatory and immune-mediated diseases.
Posted by patientexperience2025 · 47 replies
The most frequently reported adverse effects of JAK inhibitors include upper respiratory tract infections, nasopharyngitis, headache, diarrhea, and nausea, which are generally mild to moderate. More serious but less frequent complications include herpes zoster reactivation, which occurs at higher rates than with biologic therapies, as well as elevated liver enzymes and changes in lipid profiles. Anemia and neutropenia are particularly associated with JAK2-inhibiting agents like ruxolitinib. Long-term safety monitoring includes periodic lipid panels, complete blood counts, and liver function tests.
Posted by translational_research · 35 replies
First-generation JAK inhibitors such as tofacitinib and ruxolitinib inhibit multiple JAK isoforms to varying degrees, earning them the label of pan-JAK or non-selective inhibitors. Newer agents have been developed with greater selectivity: filgotinib preferentially inhibits JAK1, upadacitinib is a selective JAK1 inhibitor, and deucravacitinib selectively targets TYK2. TYK2 selectivity is particularly interesting because TYK2 is involved in IL-12 and IL-23 signaling, relevant to psoriasis, but not in hematopoietic signaling via JAK2, potentially offering a better safety profile. Greater selectivity is theorized to reduce off-target adverse effects, though long-term comparative data is still accumulating.
Join thousands of members sharing knowledge and experiences.